BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35349261)

  • 1. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabesity".
    Decara JM; Vázquez-Villa H; Brea J; Alonso M; Srivastava RK; Orio L; Alén F; Suárez J; Baixeras E; García-Cárceles J; Escobar-Peña A; Lutz B; Rodríguez R; Codesido E; Garcia-Ladona FJ; Bennett TA; Ballesteros JA; Cruces J; Loza MI; Benhamú B; Rodríguez de Fonseca F; López-Rodríguez ML
    J Med Chem; 2022 Apr; 65(7):5449-5461. PubMed ID: 35349261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study.
    Redij T; Ma J; Li Z; Hua X; Li Z
    J Comput Aided Mol Des; 2019 Nov; 33(11):973-981. PubMed ID: 31758355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
    Méndez M; Matter H; Defossa E; Kurz M; Lebreton S; Li Z; Lohmann M; Löhn M; Mors H; Podeschwa M; Rackelmann N; Riedel J; Safar P; Thorpe DS; Schäfer M; Weitz D; Breitschopf K
    J Med Chem; 2020 Mar; 63(5):2292-2307. PubMed ID: 31596080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Aminothiophene derivatives as a new class of positive allosteric modulators of glucagon-like peptide 1 receptor.
    Redij T; McKee JA; Do P; Campbell JA; Ma J; Li Z; Miller N; Srikanlaya C; Zhang D; Hua X; Li Z
    Chem Biol Drug Des; 2022 Jun; 99(6):857-867. PubMed ID: 35313084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
    Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
    J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology.
    Willard FS; Ho JD; Sloop KW
    Adv Pharmacol; 2020; 88():173-191. PubMed ID: 32416867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview, Advantages and Therapeutic Potential of Nonpeptide Positive Allosteric Modulators of Glucagon-Like Peptide-1 Receptor.
    Smelcerovic A; Lazarevic J; Tomovic K; Anastasijevic M; Jukic M; Kocic G; Anderluh M
    ChemMedChem; 2019 Mar; 14(5):514-521. PubMed ID: 30609277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.
    Cai X; Li C; Zhou J; Dai Y; Avraham Y; Sun L; Liu C; Tong J; Wang Y; Bi X; He L; Huang W; Qian H
    Bioorg Chem; 2020 Jan; 95():103538. PubMed ID: 31901754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
    Nakane A; Gotoh Y; Ichihara J; Nagata H
    Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor.
    Willard FS; Wainscott DB; Showalter AD; Stutsman C; Ma W; Cardona GR; Zink RW; Corkins CM; Chen Q; Yumibe N; Agejas J; Cumming GR; Minguez JM; Jiménez A; Mateo AI; Castaño AM; Briere DA; Sloop KW; Bueno AB
    J Med Chem; 2021 Mar; 64(6):3439-3448. PubMed ID: 33721487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency.
    Wang X; Yun Y; Chen L; Guo S; Niu B; Fang J; Yuan Q; Shen J; Xie X; Wang K
    Bioorg Med Chem; 2024 Jun; 107():117761. PubMed ID: 38795571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
    Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
    McKay NJ; Kanoski SE; Hayes MR; Daniels D
    Am J Physiol Regul Integr Comp Physiol; 2011 Dec; 301(6):R1755-64. PubMed ID: 21975647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists.
    Chen L; Yun Y; Guo S; Wang X; Xiong M; Zhao T; Xu T; Shen J; Xie X; Wang K
    J Med Chem; 2023 Jun; 66(12):7988-8010. PubMed ID: 37286364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor.
    Griffith DA; Edmonds DJ; Fortin JP; Kalgutkar AS; Kuzmiski JB; Loria PM; Saxena AR; Bagley SW; Buckeridge C; Curto JM; Derksen DR; Dias JM; Griffor MC; Han S; Jackson VM; Landis MS; Lettiere D; Limberakis C; Liu Y; Mathiowetz AM; Patel JC; Piotrowski DW; Price DA; Ruggeri RB; Tess DA
    J Med Chem; 2022 Jun; 65(12):8208-8226. PubMed ID: 35647711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.